Shots:

• Baxter has received the US FDA’s 510 (k) clearance for its PrisMax system and the integrated TherMax blood warmer for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) to treat patients with AKI and other immune diseases
• PrisMax features TrueVue Analytics tools evaluating the aggregated data- assessing the quality of CRRT program while TherMax is used to warm the blood prior to returning to the body- helping patients to keep their body temperature at a normal level               
• PrisMax system optimizes treatment accuracy and allows the hospital to connect the system to electronic medical record (EMR) platforms which reduces the documenting time with the reduction in transcription error and is available in 20+ countries with its anticipated regulatory submission in other countries in 2019 & 2020

Click here to­ read full press release/ article | Ref: Baxter | Image: Baxter